Close
CDMO Safety Testing 2026
Novotech

Quanticate Sponsors Research into Response Adaptive Trial Design

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access the Media Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Related stories

Shilpa Medicare, NXI Therapeutics AG Enters Partnership

A long-term development and commercial manufacturing agreement has been...

Cantex and Headlamp Target MS Depression Using Lumos AI

Cantex Pharmaceuticals and Headlamp Health have entered a collaboration...

VoxCell and adMare Partner on Antibody Therapy Research

VoxCell BioInnovation Inc. and adMare BioInnovations have entered a...
- Advertisement -

Quanticate, a data-focused clinical research organisation (CRO), has announced that it is partnering with Lancaster University to sponsor a STOR-i PhD project.

The partnership will see Quanticate support research into optimizing clinical trial design for rare disease and the role of response-adaptive randomisation. STOR-i was established in 2010 as an Engineering and Physical Sciences Resaearch Council EPSRC Centre for Doctoral Training and has developed an international reputation for the quality of its research.

Karen Ooms, executive vice president for corporate planning and resourcing at Quanticate, said: โ€œThis is a fantastic opportunity to bring together the knowledge and skills of the statistics department at Lancaster University with the industrial experience of a wide range of real and meaningful problems from Quanticate.

โ€œWe have been fortunate to support many companies in their rare disease programmes by providing clinical data management, biostatistics, programming, statistical consultancy and medical writing services.

โ€œThis partnership will expands on our expertise in rare diseases and enables us to further our knowledge in response-adaptive trial design.โ€

Response-adaptive trials differ from the traditional randomised approach as subjects are allocated to treatments on the basis of responses observed in the trial. Previous research and trials have suggested that response-adaptice design may have ethical benefits when applied to trials for rare diseases, without significantly compromising the power of the trial. This research seeks to extend previous work by considering the implications of delayed feedbackย  and continuous covariates on trial design and outcomes.ย  ย 
Updates on the progression of the research will be available on the Quanticate website. Further information on STOR-I is available here.

About Quanticate
Quanticate is a global data focused clinical research organisation (CRO) primarily focused on the management, analysis and reporting of data from clinical trials and post-marketing surveillance. Quanticate provides high quality teams that offer efficient outsourcing solutions for clinical data management, biostatistics, SAS programming, centralised statistical monitoring, medical writing and pharmacovigilance. Quanticate can offer study level support, functional service provision (FSP), strategic full data-services solutions or technical consultancy to meet the needs of pharmaceutical, biotechnology and device companies across the globe. Visit www.quanticate.com for further information.

Never miss a pharmaceutical headline

The pharmaceutical industry moves fast โ€“ stay on top of it with our must - read briefings.

  • The top pharma and life sciences stories, straight to your inbox
  • The biggest news, features, interviews, and analysis
  • Dedicated coverage of the key developments driving the global pharmaceutical sector

Latest stories

Related stories

Shilpa Medicare, NXI Therapeutics AG Enters Partnership

A long-term development and commercial manufacturing agreement has been...

Cantex and Headlamp Target MS Depression Using Lumos AI

Cantex Pharmaceuticals and Headlamp Health have entered a collaboration...

VoxCell and adMare Partner on Antibody Therapy Research

VoxCell BioInnovation Inc. and adMare BioInnovations have entered a...

Avenda Health Expands Unfold AI Into Midwest Cancer Care

Avenda Health said the University of Michigan Health Weiser...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access theMedia Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Translate ยป